Bioxytran, Inc. (BIXT) financial statements (2021 and earlier)

Company profile

Business Address C/O BIOXYTRAN, INC.
NEWTON, MA 02464
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 1703615113
Cash and cash equivalents 1703615113
Receivables 50 2310 
Inventory, net of allowances, customer advances and progress billings   56 
Inventory   56 
Total current assets: 2203643273
Noncurrent Assets
Property, plant and equipment   6822552
Total noncurrent assets:   6822552
TOTAL ASSETS: 220367265256
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 7223113791
Accounts payable 70   
Accrued liabilities 4319252726
Taxes payable  0   
Interest and dividends payable  4211816
Other undisclosed accounts payable and accrued liabilities 22 (34)(8)50
Debt 851227105105105
Due to related parties 96111016824
Deferred revenue and credits5  
Other undisclosed current liabilities    3231
Total current liabilities: 1,019262131342251
Noncurrent Liabilities
Other undisclosed liabilities   52  
Total liabilities: 1,019262183342251
Stockholders' equity
Stockholders' equity attributable to parent (799)(225)542(291)(195)
Preferred stock   0280
Common stock 8685105012
Additional paid in capital 1,3567214,63813,56412,978
Accumulated deficit (2,241)(383)(14,201)(13,883)(13,186)
Total stockholders' equity: (799)(225)542(291)(195)
TOTAL LIABILITIES AND EQUITY: 220367265256

Income statement (P&L) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues   191246256
Revenue, net161246256
Cost of revenue
(Cost of Goods and Services Sold)
   (104)(96)(136)
Gross profit:   87150120
Operating expenses (1,631) (398)(821)(2,212)
Operating loss: (1,631) (311)(671)(2,092)
Nonoperating expense (227)(81) (25)(8)
Interest and debt expense (42)(8)(8)(18)(8)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes 42(206)   
Loss from continuing operations before equity method investments, income taxes: (1,858)(296)(318)(714)(2,108)
Other undisclosed income from continuing operations before income taxes    188
Loss from continuing operations before income taxes: (1,858)(296)(318)(697)(2,100)
Income tax expense  (0)   
Loss from continuing operations: (1,858)(296)(318)(697)(2,100)
Loss from discontinued operations   (318)  
Net loss: (1,858)(296)(637)(697)(2,100)
Other undisclosed net income attributable to parent   318  
Net loss available to common stockholders, diluted: (1,858)(296)(318)(697)(2,100)

Comprehensive Income ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (1,858)(296)(637)(697)(2,100)
Comprehensive loss, net of tax, attributable to parent: (1,858)(296)(637)(697)(2,100)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: